ifosfamide has been researched along with Cancer of the Uterus in 76 studies
Excerpt | Relevance | Reference |
---|---|---|
"This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS)." | 9.51 | Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ( Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP, 2022) |
"To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity." | 9.12 | Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. ( Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR, 2007) |
"Adjuvant ifosfamide and cisplatin after primary surgery for stage I or II carcinosarcoma of the uterus is tolerable." | 9.11 | Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005) |
"The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival." | 9.09 | A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. ( Brunetto, VL; Hsiu, JG; Kilgore, L; Lentz, SS; McGehee, R; Olt, G; Soper, JT; Sorosky, J; Sutton, G, 2000) |
"This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy." | 9.08 | Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996) |
"A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma." | 7.83 | Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016) |
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 7.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas." | 7.73 | Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005) |
" In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy." | 7.70 | Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000) |
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1." | 7.70 | Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000) |
"The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy." | 7.68 | Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. ( Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP, 1992) |
"This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS)." | 5.51 | Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ( Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP, 2022) |
" So we compared VAC protocol and ifosfamiide for toxic effects." | 5.30 | Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998) |
"Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7." | 5.28 | Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. ( Hawkins, RE; Mansi, JL; Wiltshaw, E, 1990) |
"To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity." | 5.12 | Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. ( Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR, 2007) |
"Adjuvant ifosfamide and cisplatin after primary surgery for stage I or II carcinosarcoma of the uterus is tolerable." | 5.11 | Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005) |
"The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival." | 5.09 | A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. ( Brunetto, VL; Hsiu, JG; Kilgore, L; Lentz, SS; McGehee, R; Olt, G; Soper, JT; Sorosky, J; Sutton, G, 2000) |
"This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy." | 5.08 | Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996) |
"In advanced stage metastatic uterine carcinosarcoma as well as recurrent disease adjuvant combination, chemotherapy with ifosfamide should be considered." | 4.89 | Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. ( Bryant, A; Das, N; Galaal, K; Godfrey, K; Kucukmetin, A; Lopes, AD; Naik, R; van der Heijden, E, 2013) |
" In the primary treatment/ first line therapy of advanced stage metastatic uterine carcinosarcoma, as well as in recurrent disease, adjuvant combination chemotherapy with ifosfamide and paclitaxel should be considered." | 4.87 | Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. ( Bryant, A; Galaal, K; Godfrey, K; Kucukmetin, A; Naik, R, 2011) |
"A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma." | 3.83 | Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016) |
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 3.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
"Our study corroborates GOG 150 results, and shows that paclitaxel-carboplatin appears to be an efficacious adjuvant chemotherapy regimen for completely resected uterine carcinosarcoma." | 3.74 | A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. ( Abu-Rustum, NR; Aghajanian, CA; Alektiar, KM; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q, 2008) |
"Our data suggest a potential role for anthracycline- and ifosfamide-containing chemotherapy in the adjuvant setting for early-stage uterine sarcomas." | 3.74 | Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. ( Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Voulgaris, Z; Zorzou, MP, 2007) |
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas." | 3.73 | Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005) |
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1." | 3.70 | Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000) |
" In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy." | 3.70 | Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000) |
"The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy." | 3.68 | Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. ( Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP, 1992) |
"Uterine sarcomas are rare tumors." | 2.72 | Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. ( Fietkau, R; Gerber, B; Klautke, G; Kortmann, B; Reimer, T, 2006) |
"The response rate of 26 patients with ovarian cancer was 30." | 2.69 | [Ifosfamide combination chemotherapy for advanced gynecologic malignancies]. ( Li, X; Liu, L; Wu, L, 2000) |
"Of 21 patients with testicular tumors who could be evaluated, 10 (47%) achieved a CR." | 2.68 | High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. ( André, T; Bonnak, H; Bouleuc, C; Donsimoni, R; Esteso, A; Firmin, C; Gerota, J; Izrael, V; Lotz, JP; Merad, Z, 1995) |
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 2.67 | Gynecologic Oncology Group experience with ifosfamide. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990) |
"Among gynecologic cancers, ovarian cancer is treated with chemotherapy as a routine practice." | 2.41 | [Gynecologic cancer-evidenced based chemotherapy]. ( Ochiai, K, 2000) |
" Based on these findings, the author established a consecutive low-dose CDDP dosing method, which possibly could deliver a higher therapeutic index compared with the bolus-dosing method." | 2.40 | [Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies]. ( Shimizu, Y, 1997) |
"Ifosfamide was ineffective as adjuvant chemotherapy and there was aggressive tumor growth while the patient was on this regimen." | 2.38 | Myxoid leiomyosarcoma of the uterus. ( d'Ablaing, G; Kunzel, KE; Mills, NZ; Muderspach, LI, 1993) |
"In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses." | 2.38 | Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992) |
"Carcinosarcoma is a rare cancer, and its prognosis is poor." | 1.56 | Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. ( Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K, 2020) |
"Early-stage uterine sarcomas are managed by hysterectomy + bilateral salpingo-oophorectomy according to menopausal status and histology; lymphadenectomy is not indicated in patients without bulky nodes, and morcellation must be avoided." | 1.56 | Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). ( Aristei, C; Biondetti, PR; Cananzi, FCM; Casali, P; Ciccarone, F; Colombo, N; Comandone, A; Corvo', R; De Iaco, P; Dei Tos, AP; Donato, V; Ferrandina, G; Fiore, M; Gadducci, A; Gronchi, A; Guerriero, S; Infante, A; Lorusso, D; Odicino, F; Pirronti, T; Quagliuolo, V; Sanfilippo, R; Scambia, G; Testa, AC; Zannoni, GF, 2020) |
"Uterine mullerian adenosarcoma is a rare tumor without specific clinical symptoms and signs." | 1.36 | [Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases]. ( Guo, LN; Han, XY; Huang, HF; Pan, LY; Sheng, K; Wan, XR; Xiang, Y, 2010) |
"A case of uterine rhabdomyosarcoma is presented." | 1.31 | Rhabdomyosarcoma of the corpus of the uterus: a case report. ( Moerman, PH; Scheidt, P; Vergote, I, 2000) |
" So we compared VAC protocol and ifosfamiide for toxic effects." | 1.30 | Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998) |
"The authors report a case of encephalopathy after treatment with ifosfamide treated by a methylene blue infusion." | 1.29 | [Treatment of ifosfamide induced encephalopathy with methylene-blue]. ( Dreyfus, G; Eftekari, P; Ferrero, JM; Largillier, R; Namer, M, 1995) |
"Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7." | 1.28 | Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. ( Hawkins, RE; Mansi, JL; Wiltshaw, E, 1990) |
"Ifosfamide (IFX) has activity in a number of gynaecological malignancies and was selected for evaluation in this disease." | 1.28 | A phase II study of ifosfamide in endometrial cancer. ( Barton, C; Blackledge, G; Buxton, EJ; Meanwell, CA; Mould, JJ, 1990) |
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 1.28 | Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1989) |
"Ifosfamide and mesna were administered to 77 patients with advanced malignancies." | 1.27 | Prediction of ifosfamide/mesna associated encephalopathy. ( Blackledge, G; Blake, AE; Honigsberger, L; Kelly, KA; Meanwell, CA, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (11.84) | 18.7374 |
1990's | 20 (26.32) | 18.2507 |
2000's | 25 (32.89) | 29.6817 |
2010's | 17 (22.37) | 24.3611 |
2020's | 5 (6.58) | 2.80 |
Authors | Studies |
---|---|
Su, MH | 1 |
Wu, HH | 1 |
Huang, HY | 1 |
Lee, NR | 1 |
Chang, WH | 1 |
Lin, SC | 1 |
Chen, YJ | 1 |
Wang, PH | 3 |
Powell, MA | 1 |
Filiaci, VL | 1 |
Hensley, ML | 2 |
Huang, HQ | 1 |
Moore, KN | 1 |
Tewari, KS | 1 |
Copeland, LJ | 1 |
Secord, AA | 2 |
Mutch, DG | 1 |
Santin, A | 1 |
Warshal, DP | 1 |
Spirtos, NM | 1 |
DiSilvestro, PA | 1 |
Ioffe, OB | 2 |
Miller, DS | 1 |
Yang, ST | 1 |
Ebata, T | 1 |
Yonemori, K | 1 |
Nishikawa, T | 2 |
Sudo, K | 1 |
Shimomura, A | 1 |
Noguchi, E | 1 |
Fujiwara, Y | 1 |
Kato, T | 1 |
Hasegawa, K | 2 |
Fujiwara, K | 4 |
Tamura, K | 1 |
Ferrandina, G | 1 |
Aristei, C | 1 |
Biondetti, PR | 1 |
Cananzi, FCM | 1 |
Casali, P | 1 |
Ciccarone, F | 1 |
Colombo, N | 2 |
Comandone, A | 1 |
Corvo', R | 1 |
De Iaco, P | 1 |
Dei Tos, AP | 1 |
Donato, V | 1 |
Fiore, M | 1 |
Gadducci, A | 2 |
Gronchi, A | 1 |
Guerriero, S | 1 |
Infante, A | 1 |
Odicino, F | 1 |
Pirronti, T | 1 |
Quagliuolo, V | 1 |
Sanfilippo, R | 1 |
Testa, AC | 1 |
Zannoni, GF | 1 |
Scambia, G | 1 |
Lorusso, D | 2 |
Assi, T | 1 |
El Rassy, E | 1 |
Abi-Tayeh, G | 1 |
Sader-Ghorra, C | 1 |
Abadjian, G | 1 |
Eid, R | 1 |
Moussa, T | 1 |
Farhat, F | 1 |
Kattan, J | 1 |
Galaal, K | 2 |
van der Heijden, E | 1 |
Godfrey, K | 2 |
Naik, R | 2 |
Kucukmetin, A | 2 |
Bryant, A | 2 |
Das, N | 1 |
Lopes, AD | 1 |
Mancari, R | 1 |
Signorelli, M | 1 |
Carinelli, S | 1 |
De Ponti, E | 1 |
Sesana, S | 1 |
Corso, S | 1 |
Chiappa, V | 1 |
Lissoni, AA | 1 |
Martinelli, F | 1 |
Mancini, M | 1 |
Sarno, I | 1 |
Ditto, A | 1 |
Raspagliesi, F | 1 |
Hadoux, J | 1 |
Rey, A | 2 |
Duvillard, P | 2 |
Lhommé, C | 2 |
Balleyguier, C | 1 |
Haie-Meder, C | 2 |
Morice, P | 1 |
Tazi, Y | 1 |
Leary, A | 1 |
Larue, C | 1 |
Pautier, P | 2 |
Grignani, G | 1 |
Martín-Broto, J | 1 |
Schuler, M | 1 |
Reichardt, P | 1 |
Dandamudi, RK | 1 |
Aslam, S | 1 |
Walji, N | 1 |
El-Modir, A | 1 |
Fernando, I | 1 |
Dickson, EL | 1 |
Vogel, RI | 1 |
Gehrig, PA | 1 |
Pierce, S | 1 |
Havrilesky, L | 1 |
Dottino, J | 1 |
Fader, AN | 1 |
Ricci, S | 1 |
Geller, MA | 1 |
Matsuo, K | 1 |
Takazawa, Y | 1 |
Ross, MS | 1 |
Elishaev, E | 1 |
Podzielinski, I | 1 |
Yunokawa, M | 1 |
Sheridan, TB | 1 |
Bush, SH | 1 |
Klobocista, MM | 1 |
Blake, EA | 1 |
Takano, T | 1 |
Matsuzaki, S | 1 |
Baba, T | 1 |
Satoh, S | 1 |
Shida, M | 1 |
Ikeda, Y | 1 |
Adachi, S | 1 |
Yokoyama, T | 1 |
Takekuma, M | 1 |
Hazama, Y | 1 |
Kadogami, D | 1 |
Moffitt, MN | 1 |
Takeuchi, S | 1 |
Nishimura, M | 1 |
Iwasaki, K | 1 |
Ushioda, N | 1 |
Johnson, MS | 1 |
Yoshida, M | 1 |
Hakam, A | 1 |
Li, SW | 1 |
Richmond, AM | 1 |
Machida, H | 1 |
Mhawech-Fauceglia, P | 1 |
Ueda, Y | 1 |
Yoshino, K | 1 |
Yamaguchi, K | 1 |
Oishi, T | 1 |
Kajiwara, H | 1 |
Yasuda, M | 1 |
Kawana, K | 1 |
Suda, K | 1 |
Miyake, TM | 1 |
Moriya, T | 1 |
Yuba, Y | 1 |
Morgan, T | 1 |
Fukagawa, T | 1 |
Wakatsuki, A | 1 |
Sugiyama, T | 1 |
Pejovic, T | 1 |
Nagano, T | 1 |
Shimoya, K | 1 |
Andoh, M | 1 |
Shiki, Y | 1 |
Enomoto, T | 1 |
Sasaki, T | 1 |
Mikami, M | 1 |
Shimada, M | 1 |
Konishi, I | 1 |
Kimura, T | 1 |
Post, MD | 1 |
Shahzad, MM | 1 |
Im, DD | 1 |
Yoshida, H | 1 |
Omatsu, K | 1 |
Ueland, FR | 2 |
Kelley, JL | 1 |
Karabakhtsian, RG | 1 |
Roman, LD | 1 |
Abu-Khalaf, MM | 1 |
Raza, MA | 1 |
Hatzis, C | 1 |
Wang, H | 1 |
Lin, K | 1 |
Higgins, S | 1 |
Ratner, E | 1 |
Silasi, DA | 1 |
Azodi, M | 1 |
Rutherford, TJ | 1 |
Santin, AD | 1 |
Schwartz, PE | 1 |
Higgins, SC | 1 |
Zakashansky, K | 1 |
Bovbjerg, DH | 1 |
Hagopian, G | 1 |
Makker, V | 1 |
Abu-Rustum, NR | 1 |
Alektiar, KM | 1 |
Aghajanian, CA | 1 |
Zhou, Q | 1 |
Iasonos, A | 1 |
Han, XY | 1 |
Xiang, Y | 1 |
Guo, LN | 1 |
Sheng, K | 1 |
Wan, XR | 1 |
Huang, HF | 1 |
Pan, LY | 1 |
Liu, YL | 1 |
Tsai, SH | 1 |
Chang, FW | 1 |
Yu, MH | 1 |
Minobe, S | 1 |
Todo, Y | 1 |
Suzuki, Y | 1 |
Aoyagi, Y | 1 |
Umazume, T | 1 |
Okamoto, K | 1 |
Kato, H | 1 |
Einstein, MH | 1 |
Klobocista, M | 1 |
Hou, JY | 1 |
Lee, S | 1 |
Mutyala, S | 1 |
Mehta, K | 1 |
Reimers, LL | 1 |
Kuo, DY | 1 |
Huang, GS | 1 |
Goldberg, GL | 1 |
Chang, CC | 1 |
Wu, CC | 1 |
Floquet, A | 1 |
Gladieff, L | 1 |
Bompas, E | 1 |
Ray-Coquard, I | 1 |
Piperno-Neumann, S | 1 |
Selle, F | 2 |
Guillemet, C | 1 |
Weber, B | 1 |
Largillier, R | 2 |
Bertucci, F | 1 |
Opinel, P | 1 |
Duffaud, F | 1 |
Reynaud-Bougnoux, A | 1 |
Delcambre, C | 1 |
Isambert, N | 1 |
Kerbrat, P | 1 |
Netter-Pinon, G | 1 |
Pinto, N | 1 |
Ramondetta, LM | 2 |
Burke, TW | 1 |
Jhingran, A | 2 |
Schmandt, R | 1 |
Bevers, MW | 1 |
Wolf, JK | 1 |
Levenback, CF | 1 |
Broaddus, R | 1 |
Sutton, G | 3 |
Kauderer, J | 1 |
Carson, LF | 1 |
Lentz, SS | 2 |
Whitney, CW | 1 |
Gallion, H | 1 |
Dusenbery, KE | 1 |
Potish, RA | 1 |
Argenta, PA | 1 |
Judson, PL | 1 |
Piura, B | 1 |
Rabinovich, A | 1 |
Jeon, IS | 1 |
Lee, SM | 1 |
Ruiz Tovar, J | 1 |
Reguero Callejas, ME | 1 |
Arano Bermejo, JI | 1 |
Capote Armas, LF | 1 |
González-Palacios Martínez, F | 1 |
Cabañas Navarro, L | 1 |
Kortmann, B | 1 |
Reimer, T | 1 |
Gerber, B | 1 |
Klautke, G | 1 |
Fietkau, R | 1 |
Moreno Antón, F | 1 |
Casado Herraez, A | 1 |
Puente Vázquez, J | 1 |
Gómez Díaz, R | 1 |
Aragoncillo, P | 1 |
Díaz-Rubio García, E | 1 |
Homesley, HD | 3 |
Filiaci, V | 1 |
Markman, M | 2 |
Bitterman, P | 1 |
Eaton, L | 1 |
Kilgore, LC | 1 |
Monk, BJ | 1 |
Skubitz, KM | 1 |
Manivel, JC | 1 |
Papadimitriou, CA | 1 |
Zorzou, MP | 1 |
Markaki, S | 1 |
Rodolakis, A | 1 |
Voulgaris, Z | 1 |
Bozas, G | 1 |
Kastritis, E | 1 |
Bamias, A | 1 |
Gika, D | 1 |
Dimopoulos, MA | 1 |
Wolfson, AH | 1 |
Brady, MF | 1 |
Rocereto, T | 1 |
Mannel, RS | 1 |
Lee, YC | 1 |
Futoran, RJ | 1 |
Cohn, DE | 1 |
Brunello, A | 1 |
Basso, U | 1 |
Rossi, E | 1 |
Stefani, M | 1 |
Ghiotto, C | 1 |
Marino, D | 1 |
Crivellari, G | 1 |
Monfardini, S | 1 |
Kohno, I | 1 |
Kazuta, M | 1 |
Miyao, J | 1 |
Kunimi, N | 1 |
Kawamoto, M | 1 |
Tanimura, T | 1 |
Sekiba, K | 1 |
Ferrero, JM | 1 |
Eftekari, P | 1 |
Dreyfus, G | 1 |
Namer, M | 1 |
Garris, PD | 1 |
Gallup, DG | 1 |
Melton, K | 1 |
Lotz, JP | 2 |
André, T | 2 |
Donsimoni, R | 1 |
Firmin, C | 1 |
Bouleuc, C | 2 |
Bonnak, H | 1 |
Merad, Z | 1 |
Esteso, A | 1 |
Gerota, J | 1 |
Izrael, V | 2 |
Kunzel, KE | 1 |
Mills, NZ | 1 |
Muderspach, LI | 1 |
d'Ablaing, G | 1 |
Droz, JP | 1 |
Biron, P | 1 |
Blessing, JA | 6 |
Malfetano, JH | 1 |
Psikakos, G | 1 |
Papanicolaou, A | 1 |
Boutis, L | 1 |
Goutzioulis, M | 1 |
Makedos, G | 1 |
Papanicolaou, N | 1 |
Péne, F | 1 |
Gattegno, B | 1 |
Bazelly, B | 1 |
Houry, S | 1 |
Chapiro, J | 1 |
Gligorov, J | 1 |
Mollenkopf, A | 1 |
du Bois, A | 1 |
Meerpohl, HG | 1 |
Shimizu, Y | 1 |
van Besien, K | 1 |
Verschraegen, C | 1 |
Mehra, R | 1 |
Giralt, S | 1 |
Kudelka, AP | 1 |
Edwards, CL | 1 |
Piamsonboom, S | 1 |
Termrungruanglert, W | 1 |
Champlin, R | 1 |
Kavanagh, JJ | 1 |
Yuan, CC | 1 |
Chao, HT | 1 |
Wang, HM | 1 |
Hirota, Y | 2 |
Miyamura, K | 1 |
Hayata, T | 1 |
Miyakawa, I | 1 |
Simşek, T | 1 |
Uner, M | 1 |
Trak, B | 1 |
Erman, O | 1 |
Zorlu, GC | 1 |
Ochiai, K | 1 |
Kushner, DM | 1 |
Webster, KD | 1 |
Belinson, JL | 1 |
Rybicki, LA | 1 |
Kennedy, AW | 1 |
Hadjiliadis, D | 1 |
Govert, JA | 1 |
Scheidt, P | 1 |
Moerman, PH | 1 |
Vergote, I | 1 |
Edmonson, JH | 1 |
Brunetto, VL | 1 |
Kilgore, L | 1 |
Soper, JT | 1 |
McGehee, R | 2 |
Olt, G | 1 |
Sorosky, J | 1 |
Hsiu, JG | 1 |
Tsuda, H | 1 |
Maed, K | 1 |
Hashiguchi, Y | 1 |
Inoue, T | 1 |
Kobayashi, Y | 1 |
Umesaki, N | 1 |
Yamamoto, K | 1 |
Li, X | 1 |
Liu, L | 1 |
Wu, L | 1 |
Postovsky, S | 1 |
Beck, D | 1 |
Ben-Izhak, O | 1 |
Arush, MW | 1 |
Sutton, GP | 5 |
Manetta, A | 1 |
Homesley, H | 1 |
McGuire, W | 1 |
Barrett, RJ | 1 |
Hamaguchi, K | 1 |
Komai, K | 1 |
Sakihama, H | 1 |
Okura, N | 1 |
Nagasue, N | 2 |
Nishida, T | 2 |
Yakushiji, M | 2 |
Photopulos, G | 3 |
Berman, ML | 2 |
Hawkins, RE | 1 |
Wiltshaw, E | 1 |
Mansi, JL | 1 |
Barton, C | 1 |
Buxton, EJ | 1 |
Blackledge, G | 3 |
Mould, JJ | 2 |
Meanwell, CA | 3 |
Rosenshein, N | 1 |
DiSaia, PJ | 1 |
Blake, AE | 2 |
Latief, TN | 1 |
Blake, DR | 1 |
Shaw, IC | 1 |
Honigsberger, L | 2 |
Spooner, D | 1 |
Williams, AC | 1 |
Kelly, KA | 1 |
Kishi, N | 1 |
Imaishi, K | 1 |
Tateno, N | 1 |
Matsumura, T | 1 |
Loehrer, PJ | 1 |
Einhorn, LH | 1 |
Williams, SD | 1 |
Sawada, M | 1 |
Inagaki, M | 1 |
Hongo, J | 1 |
Ozaki, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, P[NCT00954174] | Phase 3 | 637 participants (Actual) | Interventional | 2009-08-17 | Active, not recruiting | ||
Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)[NCT02993705] | Phase 2 | 45 participants (Actual) | Interventional | 2017-02-22 | Completed | ||
"A Pilot Phase II Trial of Adjuvant Radiation Therapy Sandwiched Between Ifosfamide in Patients With Mixed Mesodermal Tumors"[NCT00231842] | Phase 2 | 30 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus[NCT00003128] | Phase 3 | 166 participants (Anticipated) | Interventional | 1997-11-30 | Completed | ||
A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus[NCT00002546] | Phase 3 | 216 participants (Anticipated) | Interventional | 1993-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Measured in months from randomization to last contact or the earlier of the date of progression or death. (NCT00954174)
Timeframe: Approximately 9 years and 7 months
Intervention | months (Median) |
---|---|
Regimen I - Uterine Carcinsarcoma Subjects | 16.3 |
Regimen II - Uterine Carcinsarcoma Subjects | 11.7 |
Regimen III - Non-uterine Carcinsarcoma Subjects | 14.6 |
Regimen IV - Non-uterine Carcinsarcoma Subjects | 10.3 |
Measured in months from randomization to last contact or death. Primary analysis was restricted to the eligible uterine carcinosarcoma cohort. (NCT00954174)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 115 months.
Intervention | months (Median) |
---|---|
Regimen I- Uterine Carcinsarcoma Subjects | 37.3 |
Regimen II - Uterine Carcinsarcoma Subjects | 29 |
Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Baseline (Pre cycle 1)
Intervention | units on a scale-baseline (Mean) |
---|---|
Regimen I - Uterine and Non-Uterine Subjects | 40.2 |
Regimen II - Uterine and Non-Uterine Subjects | 41.0 |
Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. The FACT-En TOI score ranges 0-120 with a large score suggesting better QOL. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Baseline - Prior to study treatment
Intervention | units on a scale (time point) (Mean) |
---|---|
Regimen I - Uterine and Non-Uterine Subjects | 96.2 |
Regimen II - Uterine and Non-Uterine Subjects | 97.5 |
Maximum grade experienced among all treated and eligible patients. The grades are described by severity. Grade 1 is the lowest (most mild) and Grade 5 being death (most severe). Adverse events were analyzed across cohorts since disease site was considered independent of AEs. (NCT00954174)
Timeframe: Patients were assessed for adverse events during active protocol treatment and up to 30 days after the last cycle of treatment on the protocol.
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
Regimen I - Uterine and Non-Uterine Subjects | 3 | 22 | 107 | 130 | 6 |
Regimen II - All Uterine and Non-Uterine Subjects | 3 | 80 | 97 | 61 | 3 |
Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. The FACT-En TOI score ranges 0-120 with a large score suggesting better QOL. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Prior to cycle 3, Prior to cycle 6, 30 weeks post cycle 1.
Intervention | units on a scale (time point) (Least Squares Mean) | ||
---|---|---|---|
Pre-cycle 3 | Pree-cycle 6 | 30 weeks post cycle 1 | |
Regimen I - Uterine and Non-Uterine Subjects | 93.3 | 91.6 | 98.0 |
Regimen II - Uterine and Non-Uterine Subjects | 93.3 | 91.6 | 97.6 |
Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms.Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Prior to cycle 3, Prior to cycle 6, 30 weeks post cycle 1
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Prior to cycle 3 | Prior to cycle 6 | 30 weeks post cycle 1 | |
Regimen I - Uterine and Non-Uterine Subjects | 37.2 | 34.1 | 34.8 |
Regimen II - Uterine and Non-Uterine Subjects | 37.0 | 34.2 | 34.9 |
Out of 162 planned cycles, a total of 138 cycles (85%) were administered. Number of cycles during which participants with grades 3 and 4 experienced hematologic toxicities are reported. Most of the toxicities were self-limiting. (NCT00231842)
Timeframe: 2 years
Intervention | Cycles (Number) | ||
---|---|---|---|
Neutropenia | Anemia | Thrombocytopenia | |
Grade 3 Toxicity | 11 | 6 | 6 |
Grade 4 Toxicity | 14 | 0 | 2 |
10 reviews available for ifosfamide and Cancer of the Uterus
Article | Year |
---|---|
Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dactinomycin; Desmin; F | 2017 |
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamid | 2013 |
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamid | 2011 |
On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality | 2005 |
Giant cell tumor of the uterus: case report and response to chemotherapy.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |
Myxoid leiomyosarcoma of the uterus.
Topics: Female; Humans; Ifosfamide; Leiomyosarcoma; Middle Aged; Mitotic Index; Uterine Neoplasms | 1993 |
[Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1997 |
[Gynecologic cancer-evidenced based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Evidence-Based Medicine; Femal | 2000 |
Secondary thyroid carcinoma after treatment for clear cell carcinoma of the uterus: case report and review of the literature.
Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2001 |
Gynecologic Oncology Group studies with ifosfamide.
Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita | 1992 |
14 trials available for ifosfamide and Cancer of the Uterus
Article | Year |
---|---|
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Sur | 2022 |
Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Do | 2013 |
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide; | 2003 |
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chem | 2005 |
Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Respons | 2006 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2007 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2007 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2007 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1995 |
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th | 1996 |
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2000 |
[Ifosfamide combination chemotherapy for advanced gynecologic malignancies].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; I | 2000 |
Gynecologic Oncology Group experience with ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
52 other studies available for ifosfamide and Cancer of the Uterus
Article | Year |
---|---|
Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Femal | 2022 |
Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Ifosfam | 2022 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; | 2020 |
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).
Topics: Adenosarcoma; Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Consensus; Dacarbazine; | 2020 |
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemothera | 2014 |
Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2014 |
Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modali | 2015 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma | 2015 |
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma | 2015 |
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Topics: Adult; Aged; Carcinoma; Carcinosarcoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human | 2016 |
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherap | 2016 |
Unexpected vomiting in a woman contemplating a second course of chemotherapy for carcinosarcoma of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; F | 2008 |
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Diseas | 2008 |
[Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases].
Topics: Adenosarcoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2010 |
Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged; Ne | 2010 |
Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubic | 2011 |
Beau's lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Female; Humans; Ifosfamide; Middle A | 2013 |
Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Mesn | 2005 |
Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxorubicin; Epith | 2005 |
Malignant mixed Mullerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemo | 2006 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidin | 2006 |
Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2007 |
Eleven years: the long and winding road.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; C | 2007 |
Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
Topics: Abdominal Neoplasms; Aged; Antidotes; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2007 |
[Clinical studies of ifosfamide for gynecological malignancies].
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Female; Humans; I | 1983 |
[Treatment of ifosfamide induced encephalopathy with methylene-blue].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Methylene Blue; | 1995 |
Long-term remission of previously resistant choriocarcinoma with a combination of etoposide, ifosfamide, and cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Drug Resistance; | 1995 |
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1995 |
The use of combined chemotherapy for the treatment of advanced sarcoma of the uterus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1996 |
[Sequential course and prospective management of ifosfamide-induced multi-organ toxicity].
Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modal | 1996 |
Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality | 1997 |
The VIP regimen effective treatment to refractory choriocarcinoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etoposide; Female | 1997 |
Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; Ifosf | 1997 |
Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 1998 |
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; | 2000 |
Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Diagnosis, Differential; Female; Humans; Ifosfamide; | 2000 |
Rhabdomyosarcoma of the corpus of the uterus: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Female; Humans; Hysterectomy; I | 2000 |
Are we there yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Female; Humans; Ifosfamid | 2000 |
Malignant rhabdoid tumour of the uterine cervix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo | 2001 |
Report on carcinogenesis bioassay of isophosphamide.
Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma | 1978 |
Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Agranulocytosis; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide | 1992 |
Chemotherapeutic approach to uterine papillary serous carcinoma.
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Carc | 1990 |
Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Leio | 1990 |
A phase II study of ifosfamide in endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide; | 1990 |
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci | 1989 |
Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Fem | 1989 |
Encephalopathy associated with ifosphamide/mesna therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cyclophosphamide; Female; Humans; If | 1985 |
Prediction of ifosfamide/mesna associated encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Electroencephalography; Female; Huma | 1986 |
A preliminary study of a combination chemotherapy with ifosfamide, adriamycin and cisplatin for endometrial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubi | 1988 |
VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Female; Humans; Ifosfami | 1986 |
[Ifosfamide, cisplatin, adriamycin combination chemotherapy in gynecologic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra | 1987 |